000			04077nam a22006857a 4500
008			160308s20152015 xxu||||| |||| 00| 0 eng d
022			_a1878-0938
040			_aOvid MEDLINE(R)
099			_a25977225
245			_aClinical outcomes of first- and second-generation drug-eluting stents in patients undergoing rotational atherectomy for heavily calcified coronary lesions.
251			_aCardiovascular Revascularization Medicine. 16(3):147-50, 2015 Apr-May.
252			_aCardiovasc Revasc Med. 16(3):147-50, 2015 Apr-May.
253			_aCardiovascular revascularization medicine : including molecular interventions
260			_c2015
260			_fFY2015
266			_d2016-05-24
501			_aAvailable in print through MWHC library: 2002 - present
520			_aBACKGROUND: There is paucity of data regarding the clinical outcome of second generation drug- eluting stents (DES) post rotational atherectomy (RA) for heavily calcified coronary lesions (HCCL).
520			_aCONCLUSION: The use of second generation DES, following RA for HCCL, is associated with similar short and long-term clinical outcomes to first generation DES.Copyright © 2015. Published by Elsevier Inc.
520			_aMETHODOLOGY: The study cohort comprised 99 (116 lesions) consecutive patients who underwent RA for HCCL at our institution and received either a first generation DES (40 patients, 53 lesions) or a second generation DES (59 patients, 63 lesions). The analyzed clinical parameters were the 12-month rates of death (all cause and cardiac), Q-wave MI, target lesion revascularization (TLR), definite stent thrombosis (ST) and major adverse cardiac events (MACE) defined as the composite of death, Q-wave MI, or TLR.
520			_aRESULTS: The two groups were well matched for their baseline characteristics except for a lower left ventricular ejection fraction in the second generation DES group (46.0+/-23.0% vs. 55.0+/-9.0%; p=0.02). The group receiving second generation DES had more type C lesions (81.0% vs. 58.8%; p=0.01), shorter stent length (19.9+/-6.1 mm vs. 22.7+/-7.3 mm; p=0.04) and was more likely to undergo stent postdilatation (52.4% vs. 23.1%; p=0.001). The 1-year analyzed clinical parameters were similar in the two groups: all cause death (8.5% vs. 10.3%; p=1.0), cardiac death (8.5% vs. 2.5%; p=0.40), Q-wave MI (0% vs. 0%), TLR (3.6% vs. 2.7%; p=1.0), ST (0% vs. 0%), and MACE (11.9% vs. 12.8%; p=1.0). The 1-year MACE-free survival rate was also similar in the two cohorts.
546			_aEnglish
650			_a*Atherectomy, Coronary
650			_a*Calcinosis
650			_a*Drug-Eluting Stents
650			_a*Myocardial Infarction/th [Therapy]
650			_a*Percutaneous Coronary Intervention
650			_aAdult
650			_aAged
650			_aAged, 80 and over
650			_aAtherectomy, Coronary/mt [Methods]
650			_aCardiovascular Agents/tu [Therapeutic Use]
650			_aCoronary Angiography/mt [Methods]
650			_aDrug-Eluting Stents/ae [Adverse Effects]
650			_aFemale
650			_aHumans
650			_aMale
650			_aMiddle Aged
650			_aMyocardial Infarction/pa [Pathology]
650			_aPercutaneous Coronary Intervention/mt [Methods]
650			_aRetrospective Studies
650			_aTreatment Outcome
651			_aMedStar Heart & Vascular Institute
657			_aJournal Article
700			_aChen, Fang
700			_aKiramijyan, Starkis
700			_aLhermusier, Thibault
700			_aOta, Hideaki
700			_aPendyala, Lakshmana K
700			_aPichard, Augusto D
700			_aSaar, Minha
700			_aSatler, Lowell F
700			_aSuddath, William O
700			_aTian, Wenjie
700			_aTorguson, Rebecca
700			_aWaksman, Ron
790			_aChen F, Kiramijyan S, Lhermusier T, Mahmoudi M, Ota H, Pendyala LK, Pichard AD, Saar M, Satler LF, Suddath WO, Tian W, Torguson R, Waksman R
856			_uhttp://dx.doi.org/10.1016/j.carrev.2015.02.004 _zhttp://dx.doi.org/10.1016/j.carrev.2015.02.004
942			_cART _dArticle
999			_c1760 _d1760